San Francisco, California, March 15, 2018 – A fresh business intelligence publication by TMR Research has projected the demand in the global genome editing or engineering market to expand at a notable CAGR during the forecast period of 2017 to 2025. The report, titled “Genome Editing Market – Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth and Forecast 2017 – 2025,” is a comprehensive assessment of all major factors that will determine the demand in the near future, showcases the lucrativeness of various segments and regions, and profiles some of the major companies of this market for their business overview, geographical presence, and recent strategic decisions.
Get Sample Copy of this Report @
The global genome editing market is driven by a number of factors, such as high prevalence of cancer and infectious diseases, increasing production of genetically modified corps, and rising government funding for genomics projects. In addition to that, recent technological advancements, such as the advent of highly adaptable CRISPR technology, is expected to reflect positively over the demand for genome editing in the near future. On the other hand, the prosperity of the genome editing market is strongly hindered by the lack of trained professionals, high cost of equipment, and off-target effects of CRISPR. Additionally, the requirement of a secure setup for the storage of humongous volumes of data and adverse public perception of genetic research are expected to further obstruct the market from flourishing.
Technology-wise, the genome editing market can be segmented into CRISPR, ZFN, TALEN, Antisense, Flp-In, PiggyBac, Jump-In, and Adenine Base Editor (ADE). Application-wise, the market can be bifurcated into cell line engineering, genetic engineering, therapeutics, and diagnostics.
CRISPR THERAPEUTICS, Sigma Aldrich Corporation, Thermo Fisher Scientific, Inc., Intellia Therapeutics, Inc., Sangamo, Editas Medicine, Recombinetics, Inc, and Caribou Biosciences, Inc. are a few key companies in the global genome editing market.